Die vorliegende Erfindung betrifft Verbindungen, Verfahren zur ihrer Herstellung, sie umfassende pharmazeutische Zusammensetzungen sowie ihre Verwendung bei der Behandlung und/oder Prophylaxe von Erkrankungen bei Menschen oder Tieren, insbesondere von Herz-Kreislauf-Erkrankungen, z. B. von Atherosklerose.
The invention relates to a compound of formula (I)
wherein A
1
and R
1
to R
5
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
This invention relates to new tetronic and tetramic acid derivatives with beta-secretase inhibitory activity of formula I:
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
5′
, R
6
and R
6′
are as defined hereinabove, to processes for their preparation, compositions containing said tetronic and tetramic acid derivatives and their use in the treatment and prevention of diseases modulated by an inhibitor of β-secretase, such as Alzheimer's disease.
[EN] SUBSTITUTED-PYRIDINYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS SUBSTITUÉS PAR PYRIDINYLE ET LEURS UTILISATIONS
申请人:BIONOMICS LTD
公开号:WO2019222816A1
公开(公告)日:2019-11-28
The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.
The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.